Lanzostad

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanzostad

Quick Facts

Property Description
Active Ingredient Lansoprazole
Form Delayed-Release Capsules, Orally Disintegrating Tablets (ODT)
Pharmacological Class Proton Pump Inhibitor (PPI)
Common Use Suppressing gastric (stomach) acid production
Origin Synthetic

What is Lanzostad: Definition, Origin, and Active Ingredient

Lanzostad is a pharmaceutical preparation containing the active ingredient, Lansoprazole, a synthetically derived compound used for the clinical management of stomach acid secretion. Lansoprazole is chemically classified as a substituted benzimidazole. The drug is typically available in forms like Delayed-Release Capsules, which house the active ingredient within enteric-coated granules. This specific design is a critical feature for protecting the acid-sensitive drug as it passes through the stomach, ensuring reliable absorption in the small intestine.

The Pharmacological Class: How Lanzostad Controls Gastric Acid

Lanzostad is categorized within the Proton Pump Inhibitor (PPI) pharmacological class, a highly effective group of antisecretory compounds designed to powerfully suppress gastric acid production. This classification confirms that the medicine functions by targeting the proton pump (H+/K+-ATPase enzyme system) within the stomach's parietal cells, thereby acting as an acid reducer. This mechanism achieves a significant and prolonged reduction in acid secretion, which is fundamental to its therapeutic success.

General Purpose: What Lanzostad Is Used for

The primary general purpose of Lanzostad is to provide sustained and effective suppression of gastric acidity. By minimizing the output of acid, the medication helps to relieve discomfort and manage conditions resulting from excessive stomach acid conditions. This action is broadly applied to stabilize the environment and address gastric acid-related disorders.

Regulatory References

  1. MedlinePlus
  2. Pharmacological studies

What side effects are possible with Lanzostad?

Possible Side Effects and Safety Information

The safety profile of Lanzostad (Lansoprazole) is formally categorized by regulatory bodies, classifying adverse reactions by frequency and the body system affected. These classifications establish the documented risks associated with the medicine.


Frequency-Classified Adverse Reactions

The most frequently reported effects are classified as Common (affecting up to 1 in 10 patients) and often involve the gastrointestinal and nervous systems. These include headache, dizziness, diarrhea, constipation, abdominal pain, nausea, and vomiting.

Reactions classified as Uncommon (affecting up to 1 in 100 patients) may include rash, urticaria, swelling (edema), joint pain (arthralgia), muscle pain (myalgia), and increases in liver enzymes.

Serious Adverse Reactions and Duration-Related Safety

Official regulatory documents specifically list rare but clinically significant reactions. These serious adverse reactions include severe blood disorders (e.g., agranulocytosis, pancytopenia), severe skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), acute interstitial nephritis (AIN), and anaphylactic shock.

Safety notes tied to duration of use indicate that prolonged exposure (typically one year or longer) is associated with an increased risk of bone fracture (hip, wrist, or spine) and development of hypomagnesemia (low magnesium levels). The development of fundic gland polyps is also noted with extended use.

Population-Specific Safety Considerations

Regulatory information includes specific considerations for certain patient groups. Clearance of the medicine is reduced in older adults and in patients with moderate to severe hepatic impairment (liver issues). For patients with severe hepatic impairment, caution is advised due to prolonged metabolism of the medicine, which may necessitate particular safety considerations.

Overdose and Emergency Response

Overdose Manifestations and Documented Exposure

The official regulatory documentation for Lansoprazole (the active ingredient in Lanzostad) describes the drug's profile in overdose scenarios. Clinical studies involving acute oral exposure up to 600 mg were reported, and these high doses were not associated with specific adverse reactions or clinical symptoms. However, a single, documented exposure to a substantially higher dose (1200 mg) was noted. In this isolated instance, the patient experienced transient manifestations affecting the central nervous system, specifically documented as tremor and visual disturbances. The regulatory profile does not formally document other specific, severe, or life-threatening outcomes resulting directly from acute overdose.

Emergency Action and Management

Regulatory authorities mandate specific actions if a suspected overdose of Lanzostad occurs. It is required to seek immediate medical attention and contact a Poison Control Center right away. The management approach is defined by the official statement that there is no specific antidote known for Lansoprazole. Consequently, treatment is required to be symptomatic and supportive. Regulatory information further confirms that the active substance is not significantly removed by hemodialysis. Consistent with supportive care guidelines, procedures such as gastric emptying (e.g., gastric lavage) or the administration of activated charcoal may be considered by healthcare professionals if clinically warranted.

Therapeutic Uses of Lanzostad

What Lanzostad Treats: Main Uses and Benefits

Lanzostad is prescribed to assist in the management of conditions where high stomach acid may contribute to discomfort. This medicine is used to manage symptoms related to these conditions. Clinical indications include active duodenal and benign gastric ulcers, erosive esophagitis, symptomatic gastroesesophageal reflux disease (GERD), and certain pathological hypersecretory conditions such as Zollinger-Ellison syndrome.

The medicine is generally associated with relief of acid-related discomfort. It assists patients in managing symptoms such as heartburn and acid regurgitation. For certain stomach ulcers, including those related to H. pylori bacteria or NSAID use, Lanzostad is part of a regimen that supports ulcer management.

“It is indicated for use in managing symptoms requiring a reduction in stomach acid.”


Quick Fact: Relief for Heartburn Lanzostad may be used to provide temporary relief from frequent heartburn.

Eligibility and Restrictions for Use

Eligibility for Lanzostad (Lansoprazole): Official Regulatory Summary

This section outlines who can and cannot use Lanzostad, based strictly on government-approved prescribing information.

Classification Eligibility Rule Regulatory Status
Adults mathbf18 years of age and older mathbfApproved
Pediatrics mathbf1 to mathbf17 years of age mathbfApproved (for short-term use)
Infants mathbfLess than mathbf1 year of age mathbfNot mathbfRecommended

Lanzostad is mathbfcontraindicated and mathbfmust mathbfnot mathbfbe mathbfused by patients with a known mathbfsevere hypersensitivity to Lansoprazole or any component of its formulation. Use is also mathbfprohibited for patients concurrently receiving mathbfrilpivirine-containing mathbfproducts.

Conditional Use and Restrictions

Eligibility is restricted for certain groups. The medicine should be used with caution in patients with mathbfmoderate mathbfto mathbfsevere hepatic dysfunction (liver disease), and some authorities advise mathbfdose mathbflimits for these patients and mathbfolder mathbfadults. mathbfPregnancy is a restrictive condition, as use is mathbfnot recommended. Additionally, patients with mathbfPhenylketonuria mathbf(PKU) mathbfmust avoid the orally disintegrating tablet (ODT) formulation.

What should I know about interactions with other medicines?

Lanzostad Interactions with other medicines and products

Contraindicated Combinations and Restrictions

Co-administration with the antiretroviral Atazanavir is formally contraindicated by regulatory agencies. This restriction is due to Lanzostad’s effect of raising gastric pH, which substantially reduces the absorption and systemic exposure of Atazanavir, leading to a loss of efficacy. The Orally Disintegrating Tablet (ODT) formulation also contains phenylalanine, which constitutes a documented substance restriction for patients with Phenylketonuria (PKU).


Clinically Significant Exposure Alterations

Lanzostad interacts with several medicines metabolized by the CYP2C19 and CYP3A4 enzyme systems, which can alter plasma concentrations. Co-administration is officially documented to increase the serum levels of drugs such as the immunosuppressant Tacrolimus and the antimetabolite Methotrexate. Furthermore, use with the anticoagulant Warfarin is noted in official documents to require monitoring for potential increases in the International Normalized Ratio (INR). Strong enzyme inducers, conversely, are expected to decrease Lanzostad's own systemic exposure.


Administration Timing Rules

A crucial pharmacokinetic interaction exists with food: administration 30 minutes after a meal reduces Lanzostad's systemic exposure by 50% to 70%. A mandatory timing rule applies to the gastric protectant Sucralfate: Lanzostad must be administered at least 30 minutes before this substance to prevent interference with absorption.

Mechanism of Action

Lanzostad functions as an irreversible covalent inhibitor of the H^+/ K^+-ATPase (Proton Pump), the enzyme located on the secretory surface of the gastric parietal cells. As a prodrug, it requires the highly acidic environment of these cells to be converted into its active sulfenamide metabolite.

This active form then forms a permanent disulfide bond with critical sulfhydryl groups on the H^+/ K^+-ATPase, directly and durably disabling the final step in the acid secretory pathway. The consequence of this mechanism is the inhibition of both basal and stimulated gastric acid output.

This system-level physiological modulation results in a significant and sustained reduction in the concentration of hydrochloric acid, leading to a measurable and prolonged elevation of intragastric pH.

Dosage and Administration Information

How to Use Lanzostad: Official Administration Guidelines

Lanzostad (Lansoprazole) is administered according to established protocols, ensuring that its specialized delayed-release formulation is delivered and absorbed correctly. The primary approved route of administration is oral, though an Intravenous (IV) formulation is available for use when oral therapy is not appropriate.


Standard Dosing and Timing

Indication Focus Typical Adult Dose Frequency Course Duration
Symptomatic GERD 15 mg Once daily Up to 8 weeks
Erosive Esophagitis (Treatment) 30 mg Once daily Up to 8 weeks
Pathological Hypersecretory Conditions 60 mg (initial) Once daily Adjusted individually

The standard frequency for most uses is once daily. The medication must be taken before eating (e.g., prior to breakfast) to achieve the intended suppressive effect.


Administration Requirements

Lanzostad is available as Delayed-Release Capsules and Orally Disintegrating Tablets (ODT) in strengths of 15 mg and 30 mg. To protect the enteric coating, the capsules and ODTs must not be crushed or chewed.

For patients unable to swallow the capsule, the intact pellets may be sprinkled on a tablespoon of soft food, such as applesauce, for immediate consumption.

Adjustments for Specific Populations

No dose adjustment is specified as required for older adults or those with renal impairment. However, a dose reduction is recommended for patients with severe hepatic impairment, where the daily dose should generally not exceed 30 mg.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Lanzostad

Evidence for Healing Acid-Related Damage (Erosive Esophagitis)

Research includes short-term randomized controlled trials (RCTs) for conditions involving acid-related changes to the esophagus lining, such as Erosive Esophagitis (EE). These studies were used in research exploring patient-reported experiences and applied in studies examining short-term symptom patterns related to this condition. Researchers examined outcomes related to inflammatory or irritative states and used objective measures, such as visual grading systems viewed through an endoscope, to track the repair of the esophageal tissue. Findings describe patterns observed in the studies regarding the rate of mucosal repair over follow-up periods, typically lasting between four and eight weeks. Following the initial treatment phase, research explored patterns in long-term follow-up. The follow-up durations were limited in many randomized studies designed to explore maintenance of health, and data for certain long-term outcomes remain insufficient, which contributes to the broader evidence landscape.

Evidence for Managing Symptoms of Reflux (GERD)

Lansoprazole was evaluated in research exploring symptom patterns associated with Gastroesophageal Reflux Disease (GERD), which are outcomes related to physical discomfort like heartburn. The research exploring short-term symptom changes involved clinical trials comparing Lanzoprazole to placebo (an inactive substance) or to other treatments. Studies reported measurements of changes in symptoms like heartburn severity and the total number of symptom-free days. Some reports indicated variability in the patterns of measured outcomes for symptomatic relief. However, a significant area of uncertainty is the durability of symptom relief once the short-term course of treatment is finished.

Gaps and Areas of Scientific Uncertainty

The long-term effects are not fully established through long-duration randomized controlled trials. Data for certain groups remain insufficient, especially for specific subgroups of children, pregnant individuals, or those with unique comorbidities, as evidence is limited. The comparative evidence is lacking in large-scale studies that directly assess differences in long-term outcomes between various treatments. Findings describing group patterns do not determine whether an individual will respond similarly, and certainty remains low in predicting individual outcomes based on current group research.

Frequently Asked Questions (FAQ)

Common questions about Lanzostad (FAQ)


Q: Can Lanzostad be taken long-term?

Official documents indicate that use lasting one year or longer is associated with an increased risk of specific side effects, including bone fracture and low magnesium levels (hypomagnesemia). For the over-the-counter (OTC) form, the packaging states the medicine should not be used for more than 14 days without the guidance of a healthcare professional. This duration-related information informs the discussion around long-term use.


Q: Are there certain foods or drinks I should avoid while taking Lanzostad?

Regulatory information notes that the orally disintegrating tablet (ODT) formulation contains phenylalanine and must be avoided by patients with Phenylketonuria (PKU). Beyond this specific restriction, official guidelines state the medicine should be taken before eating to promote absorption and intended effect.


Q: Does taking Lanzostad require any specific dietary changes?

Official documents primarily focus on the administration timing, stating the medicine should be taken before a meal to promote intended effect. General dietary changes are not required by the official prescribing information, although the ODT formulation is restricted for those with Phenylketonuria (PKU).


Q: Is confusion or dizziness mentioned in safety reports for Lanzostad?

Dizziness is listed in official documents as a commonly reported side effect. The symptom of confusion has been noted in rare adverse event reports, often associated with other severe conditions like low magnesium levels (hypomagnesemia) or Microscopic Colitis.


Q: Can I take my regular multivitamin while using Lanzostad?

Official information indicates that reducing stomach acid may decrease the absorption of certain nutrients, such as Vitamin B12 and potentially iron. It is noted that all supplements, including multivitamins, may need to be reviewed with a healthcare professional to determine if monitoring is necessary.


Q: Does Lanzostad start working right away?

The medicine is not intended to provide immediate relief for symptoms like heartburn. Official product information states that while some people may experience partial relief early on, it typically takes 1 to 4 days for the full acid-suppressing effect to be noticed.


Q: How long does it usually take to notice an effect from Lanzostad?

According to regulatory documents, the full acid-suppressing effect is generally noticeable within 1 to 4 days of starting treatment. The medicine is designed to provide sustained acid reduction rather than instantaneous symptom resolution.


Q: What happens if I stop taking Lanzostad suddenly?

Clinical information suggests that discontinuing the medication suddenly may result in a temporary increase in stomach acid production, sometimes referred to as 'rebound.' This temporary effect can cause a return of symptoms that are similar to the original condition.


Q: Is Lanzostad the same as the generic version of the medicine?

Lanzostad is the brand name for the active ingredient Lansoprazole. Regulatory agencies require that all generic versions of Lansoprazole be chemically identical and work in the body the same way as the brand-name product.


Q: Can Lanzostad affect my mood or sleep?

Insomnia, or sleeplessness, has been reported in clinical trials. Additionally, rare instances of more severe mental changes, such as delirium, have been noted in adverse event reports. These mental changes are sometimes connected to serious side effects like severe low magnesium levels (hypomagnesemia).


Q: Does Lanzostad have any known interactions with herbal supplements?

Official information notes that the medicine may interact with certain herbal products, specifically mentioning St. John's wort. For this reason, it is noted that a healthcare professional should be informed about all supplements and over-the-counter products being taken.


Q: Is there any difference between taking Lanzostad in the morning versus the evening?

The medication is typically prescribed as a once-daily dose. Official guidelines state that it should be taken before the first meal of the day (e.g., prior to breakfast) to promote the intended effect of prolonged acid suppression throughout the day.


Q: What is the relationship between Lanzostad and Vitamin B12 levels?

Official information states that long-term use of this medicine may interfere with the absorption of Vitamin B12, as the body requires stomach acid for this process. This potential effect is noted in regulatory documents and may require monitoring.


Q: Does Lanzostad have any known effects on the heart?

Serious adverse event reports related to low magnesium levels (hypomagnesemia) have included rare instances of ventricular arrhythmia, which is a type of irregular heart rhythm. Due to this potential connection, healthcare professionals may monitor magnesium levels during long-term use.


Q: Is there a risk of withdrawal symptoms after stopping Lanzostad?

Discontinuing the medicine may result in a temporary increase in stomach acid production. This temporary return of symptoms is not considered a true withdrawal but can be mistaken for the return of the original acid-related condition.


Q: Is Lanzostad available over the counter in some places?

Lansoprazole, the active ingredient in Lanzostad, is available in some regions both by prescription and in lower strengths as an over-the-counter (OTC) product. The OTC version is typically used by adults for the treatment of frequent heartburn.


Q: Why is Lanzostad sometimes prescribed for stomach ulcers?

Lansoprazole is officially approved for the short-term management of active stomach and duodenal ulcers. It is also a key part of combination therapies used to eliminate the H. pylori bacterium, which is a primary cause of many ulcers.


Q: What are the general expectations for a person starting Lanzostad?

General expectations, according to official information, are that the medicine will not provide immediate relief but should show its full effect within 1 to 4 days. The medication is taken once daily before a meal for the specified course duration.


Q: Is Lanzostad ever prescribed with other stomach medications?

Yes, the medicine is commonly prescribed as part of a three-drug regimen (known as triple therapy) with certain antibiotics to treat H. pylori infection in patients with stomach ulcers. This use is based on the role of the medicine in addressing the H. pylori bacterium.


Q: Does Lanzostad interact with certain antibiotics?

Lansoprazole is intentionally used alongside antibiotics as part of a regimen to treat H. pylori infection. Separately, official warnings also note that PPI use, especially when combined with antibiotics, is associated with an increased risk of developing a Clostridium difficile infection (CDI).


Q: What kinds of tests might a doctor recommend before starting Lanzostad?

Clinical protocols indicate that a doctor may recommend various tests, such as routine blood work, including checking certain blood levels or performing an upper endoscopy. Such procedures are used to gather information that supports determining the underlying cause of a patient's symptoms before beginning treatment.


Q: How quickly is Lanzostad usually eliminated from the body?

Official pharmacological data indicates that the medicine has a short elimination half-life of approximately 1.3 hours. Despite this rapid elimination, the therapeutic effect on acid suppression is long-lasting because the active component durably inhibits the acid pumps, resulting in an effect that lasts more than 24 hours.


Q: Are there any official warnings about driving while using Lanzostad?

Official patient safety information states that caution should be exercised when driving or operating heavy machinery if certain reported side effects are experienced. These effects include dizziness, sleepiness, or blurred vision, which could potentially affect concentration and motor skills.

How should Lanzostad be stored and disposed of?

How to Store and Dispose of Lanzostad

The storage and disposal of Lanzostad must adhere strictly to the conditions mandated by regulatory labeling to maintain the product’s integrity.


Official Storage Conditions

Lanzostad must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is required to protect the medicine from high heat and humidity, and the container must be kept tightly closed. For stability and safety, the product must be stored out of the sight and reach of children.

Handling and Disposal

The Orally Disintegrating Tablet (ODT) form must be used immediately after opening the individual blister unit to avoid moisture exposure. Any unused or expired Lanzostad must be disposed of according to local regulations for pharmaceutical waste; it must not be flushed down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanzostad found in:

A-Z Index: